Background

Mr. Steven A. Elms, also known as Steve, serves as the Managing Partner at Aisling Capital LLC. He joined the firm in 2000 and focuses on genomics and drug discovery technology sectors. He served as a Principal in the Life Science Investment Banking Group of Chase H&Q (formerly Hambrecht & Quist Group, J.P. Morgan H&Q Principals, LP). At H&Q, Mr. Elms was involved in over 60 financing and merger and acquisition transactions, helping clients raise, in excess of $3.3 billion ... of capital. He traded mortgage-backed securities for two years at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative at Marion Laboratories. He served for two years as a Consultant of The Wilkerson Group. He serves as the Chairman of the Board at Scerene Healthcare, Inc. He serves as the Chairman of ADMA Biologics, Inc. He serves as the Chairman of the Board at CeNeRx BioPharma, Inc and LensAR Inc. He served as Chairman of the Board at MAP Pharmaceuticals, Inc. from June 2004 to February 18, 2011. He served as the Chairman of Ambit Biosciences Corporation from July 2005 to November 2009. He served as the Chairman of Oculex Pharmaceuticals, Inc. He served as the Chairman of Adams Respiratory Therapeutics Inc. since October 14, 2005 and its Director since 2001. He has been a Director of ADMA Biologics, Inc. since 2007. He has been a Director of Loxo Oncology, Inc. since October 3, 2013. Mr. Elms serves as a Director of Advion, Inc., EarLens Corporation, CeNeRx BioPharma, Inc., NextWave Pharmaceuticals, Inc., LensAR, Inc. and Archimica SPA. He has been an independent Director of Pernix Therapeutics Holdings, Inc. since August 31, 2011 and Tria Beauty, Inc. since July 2008. Mr. Elms serves as a Director of Cidara Therapeutics, Inc. Mr. Elms served as a Director of Archimica Coöperatief U.A., Archimica SpA, and Bioenvision Inc. from May 2002 to July 13, 2011. He served as a Director of Ambit Biosciences Corporation from 2001 to June 4, 2014. He also served as a Director of Avera Pharmaceuticals Inc, Novazyme Pharmaceuticals and Oculex Pharmaceuticals, Inc. He served as a Director of MAP Pharmaceuticals, Inc. until February 18, 2011. Mr. Elms received a M.B.A. from the Kellogg School of Management at Northwestern University and a B.A. in Human Biology from Stanford University.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.